Dapagliflozin in the therapy of chronic heart failure of functional class II–III with moderately reduced ejection fraction
- 作者: Zaporozhskaya N.1, Kartashova E.1, Zheleznyak E.1
-
隶属关系:
- Rostov State Medical University, Ministry of Health of Russia
- 期: 卷 34, 编号 12 (2023)
- 页面: 30-33
- 栏目: Pharmacology
- URL: https://journals.rcsi.science/0236-3054/article/view/249760
- DOI: https://doi.org/10.29296/25877305-2023-12-06
- ID: 249760
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
The authors discuss the treatment of chronic heart failure (CHF) and present the results of our own study on the use of dapagliflozin in combination with standard therapy in patients with CHF. The comparison group consisted of patients receiving standard therapy with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-adrenoblockers and mineralocorticoid receptor antagonists.
作者简介
N. Zaporozhskaya
Rostov State Medical University, Ministry of Health of Russia
编辑信件的主要联系方式.
Email: musurivskaya@mail.ru
ORCID iD: 0000-0002-6370-035X
俄罗斯联邦, Rostov-on-Don
E. Kartashova
Rostov State Medical University, Ministry of Health of Russia
Email: musurivskaya@mail.ru
ORCID iD: 0000-0003-0912-2568
Candidate of Medical Sciences
俄罗斯联邦, Rostov-on-DonE. Zheleznyak
Rostov State Medical University, Ministry of Health of Russia
Email: musurivskaya@mail.ru
ORCID iD: 0000-0002-5165-1044
Candidate of Medical Sciences
俄罗斯联邦, Rostov-on-Don参考
- Kramer C.K., Zinman B. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annu Rev Med. 2019; 70: 323–34. doi: 10.1146/annurev-med-042017-094221.
- Wiviott S.D., Raz I., Bonaca M.P. et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018; 200: 83–9. doi: 10.1016/j.ahj.2018.01.012
- McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381 (21): 1995–2008. doi: 10.1056/NEJMoa1911303
- Dewan P., Jackson A., Lam C.S.P. et al. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. Eur J Heart Fail. 2020; 22 (5): 898–901. doi: 10.1002/ejhf.1776
- Solomon S.D., Vaduganathan M., Claggett B.L. et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020; 141 (5): 352–61. doi: 10.1161/CIRCULATIONAHA.119.044586
补充文件
